New Search

If you are not happy with the results below please do another search

1122 search results for:

481

Calypso Biotech begins dosing of first Eosinophilic Esophagitis patient in trial of CALY-002

Calypso Biotech, a leader in the development of Interleukin-15 (IL-15) targeted therapies, has begun dosing of the first Eosinophilic Esophagitis patient in the multiple dosing part of the Phase 1 clinical trial of CALY-002, a novel humanized – and highly differentiated – monoclonal antibody neutralizing IL-15. The ongoing Phase 1 clinical study of CALY-002 includes […]

486

Researchers scale production of designer immune cells for drug discovery

To prevent testing on animals and create even more precise ways of testing therapeutics, the pharmaceutical industry is increasingly turning to human immune cells. However, the availability of cells like these has been limited to date. Now, Fraunhofer researchers have succeeded in scaling the production of customized immune cells from laboratory up to industrial level.

487

Fujifilm enters into asset purchase agreement to acquire Inspirata’s digital pathology business

FUJIFILM Corporation has entered into an asset purchase agreement to acquire the global digital pathology business Inspirata, based in Tampa, Florida. Upon completion of this agreement, Inspirata’s Dynamyx digital pathology technology, employees and customers will become part of Fujifilm. The addition of digital pathology will expand Fujifilm’s robust Synapse Enterprise Imaging offering to enable the […]

488

Inivos Scientific rebrands to VITTA Group

Inivos Scientific, the parent company behind Edulab and Science & Chemical Supplies (SciChem), has rebranded and restructured the business to reflect its evolution and strategic growth plans.

489

EpiEndo commences Phase 2a Trial for EP395 in COPD patients

EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide or ‘Barriolide’, with reduced antimicrobial resistance potential, which aims to address the unmet medical need […]